Pfizer returns pagoclone to Indevus
Executive Summary
Aventis will have 90 days from Pfizer's termination of pagoclone development contract with Indevus to decide whether to take over development of the anxiolytic, Indevus says. Indevus licensed the compound from Aventis (then Rhone Poulenc-Rorer) in 1994. Pfizer told Indevus June 6 that it will not pursue the drug for generalized anxiety disorder and panic disorder after trials failed to show statistical significance over placebo...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.